Blog
RSS FeedPosted by Michael Wonder on 27 Jan 2022
Positive Early Access to Medicines Scheme (EAMS) scientific opinion awarded to GBT’s voxelotor for the treatment of haemolytic anaemia due to sickle cell disease
27 January 2022 - Global Blood Therapeutics today announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has awarded ...
Posted by Michael Wonder on 24 Jan 2022
People with chronic myeloid leukaemia granted early access to Novartis’ investigational treatment
24 January 2022 - The Medicine and Healthcare products Regulatory Agency grants positive scientific opinion on use of asciminib as 3rd-line ...
Posted by Michael Wonder on 24 Jan 2022
Patients to receive new cancer drugs faster under Brexit rules shake-up
23 January 2022 - Seven medicines already approved as changes cut as much as a month off approval times. ...
Posted by Michael Wonder on 20 Jan 2022
Jyseleca (filgotinib) licensed for the treatment of adult patients with moderately to severely active ulcerative colitis in Great Britain
18 January 2022 - Galapagos announced today that the Medicines and Healthcare products Regulatory Agency has granted a marketing authorization ...
Posted by Michael Wonder on 20 Jan 2022
NICE moves: increased accessibility and flexibility for health tech
19 January 2022 - NICE also aims to make strides in digital, genomic and antimicrobial technologies ...
Posted by Michael Wonder on 20 Jan 2022
NICE signals commitment to greater flexibility in its evaluation of promising new health technologies and making patient access fairer
20 January 2022 - Changes to the way medicines and other health technologies are evaluated by NICE for use in the ...
Posted by Michael Wonder on 19 Jan 2022
UK’s NICE to launch sweeping changes to drug assessments to be faster, more agile
19 January 2022 - The health technology assessment body has been under pressure from drugmakers and patient groups for years to ...
Posted by Michael Wonder on 11 Jan 2022
NICE recommends Rinvoq for psoriatic arthritis patients
10 January 2022 - The National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination recommending ...
Posted by Michael Wonder on 07 Jan 2022
NICE recommends MSD’s Keytruda in combination with chemotherapy for routine treatment of lung cancer
7 January 2022 - With over 48,000 new cases diagnosed per year, lung cancer is the third most common cancer ...
Posted by Michael Wonder on 26 Dec 2021
Children and young people set to benefit from new treatment for peanut allergy
23 December 2021 - Children and young people aged between 4 and 17 with a peanut allergy could be set to ...
Posted by Michael Wonder on 26 Dec 2021
MHRA approves licence extension for Novartis’ targeted therapy for advanced breast cancer patients in Great Britain
23 December 2021 - Piqray (alpelisib), in combination with fulvestrant, is approved for appropriate advanced breast cancer patients with a PIK3CA ...
Posted by Michael Wonder on 22 Dec 2021
Deciphera announces approval of Qinlock in the United Kingdom for the treatment of fourth-line gastro-intestinal stromal tumour
21 December 2021 - Qinlock significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful ...
Posted by Michael Wonder on 20 Dec 2021
NICE recommends monotherapy for adjuvant treatment of stage 3 melanoma
17 December 2021 - The approval follows a successful period of monitoring and patient access through the Cancer Drugs Fund. ...
Posted by Michael Wonder on 16 Dec 2021
NICE recommend venetoclax and azacitidine for patients with aggressive blood cancer
16 December 2021 - Venetoclax is an oral once daily treatment, which blocks the action of the B-cell lymphoma-2 protein, ...
Posted by Michael Wonder on 16 Dec 2021
NICE recommends offering PrEP to people at high risk of HIV for first time
15 December 2021 - People at the highest risk of catching HIV should be offered pre-exposure prophylaxis, NICE has recommended for ...